As compared with participants in the lowest decile, participants in the highest decile of IGF-I, IGFBP-3, IGF-I : IGFBP-3 molar ratio, and IGF-II had adjusted relative risks of pancreatic cancer of 0.98 (95% CI, 0.50–1.93), 1.28 (95% CI, 0.65–2.52), 0.93 (95% CI, 0.46–1.89), and 1.14 (95% CI, 0.58–2.24), respectively. This evidence concerns the gene IGF2 and pancreatic neoplasm.